SCHEMBL17491467

SCHEMBL17491467

O=C(Nc1cc(-c2cnco2)cc(C(F)(F)F)c1)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.66
▸ NPC1 O15118 2/20 0.66
▸ PKM P14618 2/20 0.66
▸ HTT P42858 1/20 0.55
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ JUN P05412 1/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ RHOC P08134 2/20 0.47
▸ RHOA P61586 2/20 0.47
▸ P2RX1 P51575 3/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ STAT3 P40763 1/20 0.46
▸ STAT1 P42224 1/20 0.46
▸ KCNQ3 O43525 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491420 0.89 NPC1 (0.65) KDM4ENPC1PKMKMT2AMEN1
SCHEMBL17491475 0.89 P2RX1 (0.51) KDM4ENPC1PKMHTTKMT2A
SCHEMBL17491447 0.86 IMPDH2 (0.51) KDM4ENPC1PKMKMT2AMEN1
SCHEMBL17491404 0.84 MEN1 (0.61) KDM4ENPC1PKMKMT2AMEN1
SCHEMBL17491499 0.83 P2RX1 (0.53) KDM4ENPC1PKMHTTKMT2A
SCHEMBL17491482 0.82 CES1 (0.47) KDM4ENPC1PKMALDH1A1LMNA
SCHEMBL17491415 0.80 BRAF (0.47) KDM4ENPC1PKMKMT2AMEN1
SCHEMBL11799771 0.79 P2RX1 (0.71) NPC1KMT2AMEN1RAB9AJUN
SCHEMBL17491537 0.79 TRPA1 (0.60) KDM4ENPC1HTTKMT2AMEN1
SCHEMBL17491408 0.78 EGFR (0.43) KDM4ENPC1PKMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 KDM4E 764/4885NPC1 498/4885PKM 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback